Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of “Moderate Buy” by Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $33.4545.

A number of equities research analysts have issued reports on the company. Guggenheim upped their target price on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Stephens lowered their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Finally, Evercore lifted their target price on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $20.02 on Friday. The stock has a market capitalization of $2.27 billion, a P/E ratio of -8.27 and a beta of 2.12. The business has a 50-day moving average of $22.76 and a two-hundred day moving average of $18.44. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, research analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall acquired 4,729 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were acquired at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the purchase, the chief executive officer owned 665,254 shares of the company’s stock, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This represents a 15.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.69% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. increased its position in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares during the period. JPMorgan Chase & Co. boosted its holdings in Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. Primecap Management Co. CA boosted its holdings in Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. acquired a new stake in Immunome in the 4th quarter worth $30,710,000. Finally, Sofinnova Investments Inc. increased its holdings in shares of Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after purchasing an additional 1,182,426 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.